Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors

Neuroscience and Biobehavioral Reviews

Volumn 35, Issue 3, 2011, Pages 804-817

  Berk, M ^a,b,c,d   Kapczinski, F ^e   Andreazza, A C ^e,f   Dean, O M ^a,d   Giorlando, F ^a,c   Maes, M ^g   Yucel M ^a,b   Gama, C S ^e   Dodd, S ^a,c   Dean, B ^a,d   Magalhaes P V S ^a,e   Amminger, P ^b   McGorry, P ^b   Malhi, G S ^h,i  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BARWON HEALTH   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^e HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g Piyavate Hospital   (Thailand)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

BDNF; Bipolar disorders; Cytokines; Depression neuroprotection; Early intervention; Lipids; Mania; Mitochondria; Neuroprogression; Neurotrophins; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CARBAMAZEPINE; CELECOXIB; CORTICOSTEROID; DOCOSAHEXAENOIC ACID; FLUOXETINE; GAMMA INTERFERON; GLUTAMIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LAMOTRIGINE; LITHIUM; MONOAMINE; NEUROTROPHIC FACTOR; NEUROTROPHIN; OMEGA 3 FATTY ACID; PLACEBO; PROTEIN BCL 2; QUETIAPINE; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ANTIINFLAMMATORY ACTIVITY; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; DEPRESSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC SYSTEM; EPIGENETICS; HUMAN; INFLAMMATION; MITOCHONDRIAL ENERGY TRANSFER; NEUROLOGIC DISEASE; NEUROPROTECTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SECOND MESSENGER;

ANIMALS; BIPOLAR DISORDER; CYTOKINES; DISEASE PROGRESSION; HUMANS; INFLAMMATION; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; OXIDATIVE STRESS;

EID: 78649938042     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2010.10.001     Document Type: Review

References (215)

1. Almeida O.P., Alfonso H., Jamrozik K., Hankey G.J., Flicker L. Aspirin use, depression, and cognitive impairment in later life: the health in men study. J. Am. Geriatr. Soc. 2010, 58:990-992.
2. Amminger G.P., Schafer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67:146-154.
3. Andreazza A. S02-02 Mitochondrial dysfunction and oxidative stress in bipolar disorder. Eur. Psychiatry 2009, 24:S15.
4. Andreazza A.C., Cassini C., Rosa A.R., Leite M.C., de Almeida L.M., Nardin P., Cunha A.B., Cereser K.M., Santin A., Gottfried C., Salvador M., Kapczinski F., Goncalves C.A. Serum S100B and antioxidant enzymes in bipolar patients. J. Psychiatr. Res. 2007, 41:523-529.
5. Andreazza A.C., Kapczinski F., Kauer-Sant'Anna M., Walz J.C., Bond D.J., Goncalves C.A., Young L.T., Yatham L.N. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J. Psychiatry Neurosci. 2009, 34:263-271.
6. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.-M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J. Neurosci. Res. 2003, 71:127-131.
7. Bai O., Wei Z., Lu W., Bowen R., Keegan D., Li X.M. Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal. J. Neurosci. Res. 2002, 69:278-283.
8. Bai O., Zhang H., Li X.-M. Antipsychotic drugs clozapine and olanzapine upregulate bcl-2 mRNA and protein in rat frontal cortex and hippocampus. Brain Res. 2004, 1010.
9. Baxter L.R., Phelps M.E., Mazziotta J.C., Schwartz J.M., Gerner R.H., Selin C.E., Sumida R.M. Cerebral metabolic rates for glucose in mood disorders. Studies with positron emission tomography and fluorodeoxyglucose F 18. Arch. Gen. Psychiatry 1985, 42:441-447.
10. Bazinet R.P., Rao J.S., Chang L., Rapoport S.I., Lee H.J. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder. Biol. Psychiatry 2006, 59:401-407.
11. Behrens M.M., Ali S.S., Dugan L.L. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J. Neurosci. 2008, 28:13957-13966.
12. Berger G., Dell'Olio M., Amminger P., Cornblatt B., Phillips L., Yung A., Yan Y., Berk M., McGorry P. Neuroprotection in emerging psychotic disorders. Early Interv. Psychiatry 2007, 1:114-127.
13. Berger G.E., Wood S.J., Wellard R.M., Proffitt T.M., McConchie M., Amminger G.P., Jackson G.D., Velakoulis D., Pantelis C., McGorry P.D. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Neuropsychopharmacology 2008, 33:2467-2473.
14. Berger I., Segal I., Shmueli D., Saada A. The effect of antiepileptic drugs on mitochondrial activity: a pilot study. J. Child Neurol. 2010, 25:541-545.
15. Berk M., Bodemer W., van Oudenhove T., Butkow N. Dopamine increases platelet intracellular calcium in bipolar affective disorder and controls. Int. Clin. Psychopharmacol. 1994, 9:291-293.
16. Berk M., Bodemer W., Van Oudenhove T., Butkow N. The platelet intracellular calcium response to serotonin is augmented in bipolar manic and depressed patients. Hum. Psychopharmacol. 1995, 10:189-193.
17. Berk M., Conus P., Lucas N., Hallam K., Malhi G.S., Dodd S., Yatham L.N., Yung A., McGorry P. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 2007, 9:671-678.
18. Berk M., Copolov D.L., Dean O., Lu K., Jeavons S., Schapkaitz I., Anderson-Hunt M., Bush A.I. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol. Psychiatry 2008, 64:468-475.
19. Berk M., Copolov D.L., Dean O., Lu K., Jeavons S., Schapkaitz I., Anderson-Hunt M., Bush A.I. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol. Psychiatry 2008.
20. Berk M., Copolov D.L., Dean O., Lu K., Jeavons S., Shapkaitz I., Anderson-Hunt M., Bush A.I. Antioxidant treatment of the glutathione deficiency in bipolar disorder with N-acetylcysteine: a double-blind randomised placebo controlled trial. Bipolar Disorders 2007, 9:8-9.
21. Berk M., Dodd S. Efficacy of atypical antipsychotics in bipolar disorder. Drugs 2005, 65:257-269.
22. Berk M., Dodd S., Kauer-Sant'anna M., Malhi G.S., Bourin M., Kapczinski F., Norman T. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. Suppl. 2007, 41-49.
23. Berk M., Hallam K.T., McGorry P.D. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J. Affect. Disord. 2007, 100:279-280.
24. Berk M., Ng F., Dean O., Dodd S., Bush A.I. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol. Sci. 2008, 29:346-351.
25. Berk M., Plein H., Belsham B. The specificity of platelet glutamate receptor supersensitivity in psychotic disorders. Life Sci. 2000, 66:2427-2432.
26. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 1999, 73:1127-1137.
27. Bian Q., Kato T., Monji A., Hashioka S., Mizoguchi Y., Horikawa H., Kanba S. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:42-48.
28. Boer U., Cierny I., Krause D., Heinrich A., Lin H., Mayr G., Hiemke C., Knepel W. Chronic lithium salt treatment reduces CRE/CREB-directed gene transcription and reverses its upregulation by chronic psychosocial stress in transgenic reporter gene mice. Neuropsychopharmacology 2008, 33:2407-2415.
29. Bora E., Fornito A., Yucel M., Pantelis C. Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. Biol. Psychiatry 2010, 67:1097-1105.
30. Bora E., Yucel M., Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J. Affect. Disord. 2009, 113:1-20.
31. Bosetti F., Rintala J., Seemann R., Rosenberger T.A., Contreras M.A., Rapoport S.I., Chang M.C. Chronic lithium downregulates cyclooxygenase-2 activity and prostaglandin E(2) concentration in rat brain. Mol. Psychiatry 2002, 7:845-850.
32. Brady K., Goldberg J.F. Substance abuse and bipolar disorder. Proceedings of the 9th Annual US Psychiatric and Mental Health Congress 1996.
33. Brietzke E., Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1355-1361.
34. Brietzke E., Kauer-Sant'Anna M., Teixeira A.L., Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav. Immun. 2009, 23:1079-1082.
35. Brietzke E., Stertz L., Fernandes B.S., Kauer-Sant'anna M., Mascarenhas M., Escosteguy Vargas A., Chies J.A., Kapczinski F. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J. Affect. Disord. 2009, 116:214-217.
36. Brunello N., Alboni S., Capone G., Benatti C., Blom J.M., Tascedda F., Kriwin P., Mendlewicz J. Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int. Clin. Psychopharmacol. 2006, 21:219-225.
37. Caliyurt O., Altiay G. Resting energy expenditure in manic episode. Bipolar Disord. 2009, 11:102-106.
38. Chalecka-Franaszek E., Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:8745-8750.
39. Chang Y.C., Rapoport S.I., Rao J.S. Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex. Neurochem. Res. 2009, 34:536-541.
40. Chen G., Huang L.D., Jiang Y.M., Manji H.K. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 1999, 72:1327-1330.
41. Chen Y., Sharma R.P., Costa R.H., Costa E., Grayson D.R. On the epigenetic regulation of the human reelin promoter. Nucleic Acids Res. 2002, 30:2930-2939.
42. Cheng R., Juo S.H., Loth J.E., Nee J., Iossifov I., Blumenthal R., Sharpe L., Kanyas K., Lerer B., Lilliston B., Smith M., Trautman K., Gilliam T.C., Endicott J., Baron M. Genome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol. Psychiatry 2006, 11:252-260.
43. Chengappa K.N., Suppes T., Berk M. Treatment of bipolar mania with atypical antipsychotics. Expert Rev. Neurother. 2004, 4:S17-25.
44. Cherlyn S.Y., Woon P.S., Liu J.J., Ong W.Y., Tsai G.C., Sim K. Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. Neurosci. Biobehav. Rev. 2010, 34:958-977.
45. Choi D.W., Maulucci-Gedde M., Kriegstein A.R. Glutamate neurotoxicity in cortical cell culture. J. Neurosci. 1987, 7:357-368.
46. Connor T.J., Leonard B.E. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 1998, 62:583-606.
47. Conus P., McGorry P.D. First-episode mania: a neglected priority for early intervention. Aust. N Z J. Psychiatry 2002, 36:158-172.
48. Cui J., Shao L., Young L.T., Wang J.F. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 2007, 144:1447-1453.
49. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A., Santin A., Kapczinski F. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 2006, 398:215-219.
50. de Oliveira G.S., Cereser K.M., Fernandes B.S., Kauer-Sant'Anna M., Fries G.R., Stertz L., Aguiar B., Pfaffenseller B., Kapczinski F. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J. Psychiatr. Res. 2009, 43:1171-1174.
51. Dean B., Tawadros N., Scarr E., Gibbons A.S. Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J. Affect. Disord. 2009, 120:245-248.
52. DelBello M.P., Strakowski S.M., Zimmerman M.E., Hawkins J.M., Sax K.W. MRI analysis of the cerebellum in bipolar disorder: a pilot study. Neuropsychopharmacology 1999, 21:63-68.
53. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., Kammerer W.A., Quezado Z., Luckenbaugh D.A., Salvadore G., Machado-Vieira R., Manji H.K., Zarate C.A. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010, 67:793-802.
54. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:952-955.
55. Dodd S., Berk M. Predictors of antidepressant response: a selective review. Int. J. Psychiatry Clin. Pract. 2004, 8:91-100.
56. Dodd S., Dean O., Copolov D.L., Malhi G.S., Berk M. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Exp. Opin. Biol. Ther. 2008, 8:1955-1962.
57. Drexhage R.C., Knijff E.M., Padmos R.C., Heul-Nieuwenhuijzen L., Beumer W., Versnel M.A., Drexhage H.A. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Exp. Rev. Neurother. 2010, 10:59-76.
58. El-Badri S., Ashton C., Moore P., Marsh V., Ferrier I. Electrophysiological and cognitive function in young euthymic patients with bipolar affective disorder. Bipolar Disorder. 2001, 3:79-87.
59. Eren I., Naziroglu M., Demirdas A. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem. Res. 2007, 32:1188-1195.
60. Fattal O., Link J., Quinn K., Cohen B.H., Franco K. Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr. 2007, 12:429-438.
61. Fernandes B.S., Gama C.S., Kauer-Sant'Anna M., Lobato M.I., Belmonte-de-Abreu P., Kapczinski F. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J. Psychiatr. Res. 2009, 43:1200-1204.
62. Fernandez-Riejos P., Najib S., Santos-Alvarez J., Martin-Romero C., Perez-Perez A., Gonzalez-Yanes C., Sanchez-Margalet V. Role of leptin in the activation of immune cells. Mediators Inflamm. 2010, 568343.
63. Ferreira F.R., Biojone C., Joca S.R., Guimaraes F.S. Antidepressant-like effects of N-acetyl-L-cysteine in rats. Behav. Pharmacol. 2008, 19:747-750.
64. Forester B.P., Finn C.T., Berlow Y.A., Wardrop M., Renshaw P.F., Moore C.M. Brain lithium, N-acetyl aspartate and myo-inositol levels in older adults with bipolar disorder treated with lithium: a lithium-7 and proton magnetic resonance spectroscopy study. Bipolar Disord. 2008, 10:691-700.
65. Fornito A., Malhi G.S., Lagopoulos J., Ivanovski B., Wood S.J., Velakoulis D., Saling M.M., McGorry P.D., Pantelis C., Yucel M. In vivo evidence for early neurodevelopmental anomaly of the anterior cingulate cortex in bipolar disorder. Acta Psychiatr. Scand. 2007, 116:467-472.
66. Fornito A., Yucel M., Wood S.J., Bechdolf A., Carter S., Adamson C., Velakoulis D., Saling M.M., McGorry P.D., Pantelis C. Anterior cingulate cortex abnormalities associated with a first psychotic episode in bipolar disorder. Br. J. Psychiatry 2009, 194:426-433.
67. Foster A.C., Vezzani A., French E.D., Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett. 1984, 48:273-278.
68. Franchini L., Zanardi R., Smeraldi E., Gasperini M. Early onset of lithium prophylaxis as a predictor of good long-term outcome. Eur. Arch. Psychiatry Clin. Neurosci. 1999, 249:227-230.
69. Frey B.N., Martins M.R., Petronilho F.C., Dal-Pizzol F., Quevedo J., Kapczinski F. Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord. 2006, 8:275-280.
70. Frey B.N., Valvassori S.S., Reus G.Z., Martins M.R., Petronilho F.C., Bardini K., Dal-Pizzol F., Kapczinski F., Quevedo J. Changes in antioxidant defense enzymes after D-amphetamine exposure: implications as an animal model of mania. Neurochem. Res. 2006, 31:699-703.
71. Frye M.A., Watzl J., Banakar S., O'Neill J., Mintz J., Davanzo P., Fischer J., Chirichigno J.W., Ventura J., Elman S., Tsuang J., Walot I., Thomas M.A. Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology 2007, 32:2490-2499.
72. Fryer A.D., Jacoby D.B. Effect of inflammatory cell mediators on M2 muscarinic receptors in the lungs. Life Sci. 1993, 52:529-536.
73. Galecki P., Szemraj J., Bienkiewicz M., Zboralski K., Galecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum. Psychopharmacol. 2009, 24:277-286.
74. Gibbons A.S., Scarr E., McLean C., Sundram S., Dean B. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J. Affect. Disord. 2009, 116:184-191.
75. Goldberg J.F., Ernst C.L. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J. Clin. Psychiatry 2002, 63:985-991.
76. Goldstein B.I., Kemp D.E., Soczynska J.K., McIntyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry 2009, 70:1078-1090.
77. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
78. Gould T.D., Picchini A.M., Einat H., Manji H.K. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr. Drug Targets 2006, 7:1399-1409.
79. Graham D.G., Tiffany S.M., Bell W.R., Gutknecht W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 1978, 14:644-653.
80. Grant J.E., Kim S.W., Odlaug B.L. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol. Psychiatry 2007.
81. Grayson D.R., Kundakovic M., Sharma R.P. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?. Mol. Pharmacol. 2010, 77:126-135.
82. Green K., Brand M.D., Murphy M.P. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 2004, 53(Suppl. 1):S110-S118.
83. Grima G., Benz B., Parpura V., Cuenod M., Do K.Q. Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia. Schizophr. Res. 2003, 62:213-224.
84. Grimes C.A., Jope R.S. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J. Neurochem. 2001, 78:1219-1232.
85. Guo S., Arai K., Stins M.F., Chuang D.M., Lo E.H. Lithium upregulates vascular endothelial growth factor in brain endothelial cells and astrocytes. Stroke 2009, 40:652-655.
86. Haddad E.B., Rousell J., Lindsay M.A., Barnes P.J. Synergy between tumor necrosis factor alpha and interleukin 1beta in inducing transcriptional down-regulation of muscarinic M2 receptor gene expression. Involvement of protein kinase A and ceramide pathways. J. Biol. Chem. 1996, 271:32586-32592.
87. Hawton K., Sutton L., Haw C., Sinclair J., Harriss L. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. J. Clin. Psychiatry 2005.
88. Ichiyama T., Okada K., Lipton J.M., Matsubara T., Hayashi T., Furukawa S. Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res. 2000, 857:246-251.
89. Iwamoto K., Bundo M., Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum. Mol. Genet. 2005, 14:241-253.
90. Jacka F.N., Pasco J.A., Mykletun A., Williams L.J., Hodge A.M., O'Reilly S.L., Nicholson G.C., Kotowicz M.A., Berk M. Association of Western and traditional diets with depression and anxiety in women. Am. J. Psychiatry 2010, 167:305-311.
91. Jacka F.N., Williams L.J., Pasco J.A., Mykletun A., Berk M. The role of omega-3 fatty acids in the prevention and treatment of the common mental disorders. J. Affect. Disord. 2010, 122:S17.
92. Ji B., La Y., Gao L., Zhu H., Tian N., Zhang M., Yang Y., Zhao X., Tang R., Ma G., Zhou J., Meng J., Ma J., Zhang Z., Li H., Feng G., Wang Y., He L., Wan C. A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. J. Proteome Res. 2009, 8:3633-3641.
93. Jones K.A., Porjesz B., Almasy L., Bierut L., Goate A., Wang J.C., Dick D.M., Hinrichs A., Kwon J., Rice J.P., Rohrbaugh J., Stock H., Wu W., Bauer L.O., Chorlian D.B., Crowe R.R., Edenberg H.J., Foroud T., Hesselbrock V., Kuperman S., Nurnberger J., O'Connor S.J., Schuckit M.A., Stimus A.T., Tischfield J.A., Reich T., Begleiter H. Linkage and linkage disequilibrium of evoked EEG oscillations with CHRM2 receptor gene polymorphisms: implications for human brain dynamics and cognition. Int. J. Psychophysiol. 2004, 53:75-90.
94. Kapczinski F., Dal-Pizzol F., Teixeira A.L., Magalhaes P.V., Kauer-Sant'anna M., Klamt F., de Bittencourt Pasquali M.A., Quevedo J., Gama C.S., Post R. A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol. Psychiatry 2010, 15:784-786.
95. Kapczinski F., Frey B.N., Kauer-Sant'Anna M., Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Exp. Rev. Neurother. 2008, 8:1101-1113.
96. Kapczinski F., Vieta E., Andreazza A.C., Frey B.N., Gomes F.A., Tramontina J., Kauer-Sant'anna M., Grassi-Oliveira R., Post R.M. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci. Biobehav. Rev. 2008, 32:675-692.
97. Kato T. Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. CNS Drugs 2007, 21:1-11.
98. Kato T., Iwamoto K., Kakiuchi C., Kuratomi G., Okazaki Y. Genetic or epigenetic difference causing discordance between monozygotic twins as a clue to molecular basis of mental disorders. Mol. Psychiatry 2005, 10:622-630.
99. Kauer-Sant'Anna M., Kapczinski F., Andreazza A.C., Bond D.J., Lam R.W., Young L.T., Yatham L.N. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int. J. Neuropsychopharmacol. 2009, 12:447-458.
100. Kessing L.V., Andersen P.K., Mortensen P.B. Predictors of recurrence in affective disorder: a case register study. J. Affect. Disord. 1998, 49:101-108.
101. Kim H.W., Rapoport S.I., Rao J.S. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol. Dis. 2009, 37:596-603.
102. Kim S.W., Jeong J.Y., Kim H.J., Seo J.S., Han P.L., Yoon S.H., Lee J.K. Combination treatment with ethyl pyruvate and aspirin enhances neuroprotection in the postischemic brain. Neurotox. Res. 2010, 17:39-49.
103. Kim Y.J., Ko H.H., Han E.S., Lee C.S. Lamotrigine inhibition of rotenone- or 1-methyl-4-phenylpyridinium-induced mitochondrial damage and cell death. Brain Res. Bull. 2007, 71:633-640.
104. Kim Y.K., Jung H.G., Myint A.M., Kim H., Park S.H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J. Affect. Disord. 2007, 104:91-95.
105. Knijff E.M., Breunis M.N., Kupka R.W., de Wit H.J., Ruwhof C., Akkerhuis G.W., Nolen W.A., Drexhage H.A. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007, 9:743-753.
106. Konradi C., Eaton M., MacDonald M.L., Walsh J., Benes F.M., Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch. Gen. Psychiatry 2004, 61:300-308.
107. Kraepelin E. Manic Depressive Insanity and Paranoia 1921, Thoemmes Press, Bristol.
108. Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., Epperson C.N., Goddard A., Mason G.F. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry 2002, 7(Suppl. 1):S71-80.
109. Laan W., Grobbee D.E., Selten J.P., Heijnen C.J., Kahn R.S., Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2010, 71:520-527.
110. Lanquillon S., Krieg J.C., Bening-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379.
111. Lante F., Meunier J., Guiramand J., Maurice T., Cavalier M., de Jesus Ferreira M.C., Aimar R., Cohen-Solal C., Vignes M., Barbanel G. Neurodevelopmental damage after prenatal infection: role of oxidative stress in the fetal brain. Free Radic. Biol. Med. 2007, 42:1231-1245.
112. LaRowe S.D., Myrick H., Hedden S., Mardikian P., Saladin M., McRae A., Brady K., Kalivas P.W., Malcolm R. Is cocaine desire reduced by N-acetylcysteine?. Am. J. Psychiatry 2007, 164:1115-1117.
113. Laux I., Nel A. Evidence that oxidative stress-induced apoptosis by menadione involves Fas-dependent and Fas-independent pathways. Clin. Immunol. 2001, 101:335-344.
114. Lee H.J., Ertley R.N., Rapoport S.I., Bazinet R.P., Rao J.S. Chronic administration of lamotrigine downregulates COX-2 mRNA and protein in rat frontal cortex. Neurochem. Res. 2008, 33:861-866.
115. Lenaz G., D'Aurelio M., Merlo Pich M., Genova M.L., Ventura B., Bovina C., Formiggini G., Parenti Castelli G. Mitochondrial bioenergetics in aging. Biochim. Biophys. Acta 2000, 1459:397-404.
116. Li T., Zuo X., Zhou Y., Wang Y., Zhuang H., Zhang L., Zhang H., Xiao X. The vagus nerve and nicotinic receptors involve inhibition of HMGB1 release and early pro-inflammatory cytokines function in collagen-induced arthritis. J. Clin. Immunol. 2010, 30:213-220.
117. Lohoff F.W., Sander T., Ferraro T.N., Dahl J.P., Gallinat J., Berrettini W.H. Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 139B:51-53.
118. Lopez, C., Cortez, V., Palacio, C., Gallo, A., Lopera, J., Garcia, J., 2008. Effects of chronicity on the cognitive performance of patients with bipolar disorder type 1. In: ISBD Conference. Department of Psychiatry, School of Medicine, Universidad De Antioquia, Medellin, Colombia.
119. Luo C., Xu H., Li X.M. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res. 2005, 1063:32-39.
120. Lyoo I.K., Sung Y.H., Dager S.R., Friedman S.D., Lee J.Y., Kim S.J., Kim N., Dunner D.L., Renshaw P.F. Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord. 2006, 8:65-74.
121. Machado-Vieira R., Andreazza A.C., Viale C.I., Zanatto V., Cereser V., da Silva Vargas R., Kapczinski F., Portela L.V., Souza D.O., Salvador M., Gentil V. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci. Lett. 2007, 421:33-36.
122. Machado-Vieira R., Dietrich M.O., Leke R., Cereser V.H., Zanatto V., Kapczinski F., Souza D.O., Portela L.V., Gentil V. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol. Psychiatry 2007, 61:142-144.
123. Machado-Vieira R., Manji H.K., Zarate C.A. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009, 15:525-539.
124. Maes M. A review on the acute phase response in major depression. Rev. Neurosci. 1993, 4:407-416.
125. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 1995, 29:141-152.
126. Maes M., Delange J., Ranjan R., Meltzer H.Y., Desnyder R., Cooremans W., Scharpe S. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 1997, 66:1-11.
127. Maes M., Lin A.H., Verkerk R., Delmeire L., Van Gastel A., Van der Planken M., Scharpe S. Serotonergic and noradrenergic markers of post-traumatic stress disorder with and without major depression. Neuropsychopharmacology 1999, 20:188-197.
128. Mahadik S.P., Evans D., Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25:463-493.
129. Maker H.S., Weiss C., Silides D.J., Cohen G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J. Neurochem. 1981, 36:589-593.
130. Malhi G.S., Valenzuela M., Wen W., Sachdev P. Magnetic resonance spectroscopy and its applications in psychiatry. Austral. NZ J. Psychiatry 2002, 36:31-43.
131. Malhi G.S., Yatham L.N. Mania matters!. Acta Psychiatrica Scand. 2007, 116:1-2.
132. Malhi G.S., Berk M., Bourin M., Ivanovski B., Dodd S., Lagopoulos J., Mitchell P.B. A typical mood stabilizers: a "typical role for atypical antipsychotics. Acta Psychiatr. Scand. Suppl. 2005, 29-38.
133. Malhi G.S., Ivanovski B., Hadzi-Pavlovic D., Mitchell P.B., Vieta E., Sachdev P. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord. 2007, 9:114-125.
134. Manji H.K., Lenox R.H. The nature of bipolar disorder. J. Clin. Psychiatry 2000, 61(Suppl. 13):42-57.
135. Manji H.K., Moore G.J., Rajkowska G., Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol. Psychiatry 2000, 5:578-593.
136. Mardikian P.N., LaRowe S.D., Hedden S., Kalivas P.W., Malcolm R.J. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:389-394.
137. Martinez-Aran A., Vieta E., Torrent C., Sanchez-Moreno J., Goikolea J.M., Salamero M., Malhi G.S., Gonzalez-Pinto A., Daban C., Alvarez-Grandi S., Fountoulakis K., Kaprinis G., Tabares-Seisdedos R., Ayuso-Mateos J.L. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord. 2007, 9:103-113.
138. Martinowich K., Manji H.K., Lu B. New perspective of BDNF cell biology and its implications in depression. Nat. Neurosci. 2007, 10:1089-1093.
139. Matsuo K., Walss-Bass C., Nery F.G., Nicoletti M.A., Hatch J.P., Frey B.N., Monkul E.S., Zunta-Soares G.B., Bowden C.L., Escamilla M.A., Soares J.C. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder. Neuropsychopharmacology 2009, 34:1904-1913.
140. Matza L.S., Rajagopalan K.S., Thompson C.L., De Lissovoy G. Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. J. Clin. Psychiatry 2005, 66:1432-1440.
141. Maurer I.C., Schippel P., Volz H.P. Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord. 2009, 11:515-522.
142. McEwen B.S. Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Ann. N. Y. Acad. Sci. 2004, 1032:1-7.
143. McGorry P.D., Hickie I.B., Yung A.R., Pantelis C., Jackson H.J. clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Austral. N Z J.Psychiatry 2006, 40:616-622.
144. Mendlewicz J., Kriwin P., Oswald P., Souery D., Alboni S., Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int. Clin. Psychopharmacol. 2006, 21:227-231.
145. Meyer J.M., McEvoy J.P., Davis V.G., Goff D.C., Nasrallah H.A., Davis S.M., Hsiao J.K., Swartz M.S., Stroup T.S., Lieberman J.A. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol. Psychiatry 2009, 66:1013-1022.
146. Miller C.L., Llenos I.C., Dulay J.R., Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 2006, 1073-1074:25-37.
147. Montgomery P., Richardson A.J. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst. Rev. 2008, CD005169.
148. Moore G.J., Bebchuk J.M., Hasanat K., Chen G., Seraji-Bozorgzad N., Wilds I.B., Faulk M.W., Koch S., Glitz D.A., Jolkovsky L., Manji H.K. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?. Biol. Psychiatry 2000, 48.
149. Moore G.J., Bebchuk J.M., Wilds I.B., Chen G., Manji H.K., Menji H.K. Lithium-induced increase in human brain grey matter. Lancet 2000, 356:1241-1242.
150. Muller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 2007, 12:988-1000.
151. Myint A.M., Kim Y.K., Verkerk R., Park S.H., Scharpe S., Steinbusch
152. Nakamura M., Salisbury D.F., Hirayasu Y., Bouix S., Pohl K.M., Yoshida T., Koo M.S., Shenton M.E., McCarley R.W. Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study. Biol. Psychiatry 2007, 62:773-783.
153. Nery F.G., Monkul E.S., Hatch J.P., Fonseca M., Zunta-Soares G.B., Frey B.N., Bowden C.L., Soares J.C. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum. Psychopharmacol. 2008, 23:87-94.
154. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 2008, 1-26.
155. Obata T. Dopamine efflux by MPTP and hydroxyl radical generation. J. Neural Transm. 2002, 109:1159-1180.
156. Ortiz-Dominguez A., Hernandez M.E., Berlanga C., Gutierrez-Mora D., Moreno J., Heinze G., Pavon L. Immune variations in bipolar disorder: phasic differences. Bipolar Disord. 2007, 9:596-602.
157. Paintlia M.K., Paintlia A.S., Khan M., Singh I., Singh A.K. Modulation of peroxisome proliferator-activated receptor-alpha activity by N-acetyl cysteine attenuates inhibition of oligodendrocyte development in lipopolysaccharide stimulated mixed glial cultures. J. Neurochem. 2008, 105:956-970.
158. Paintlia M.K., Paintlia A.S., Singh A.K., Singh I. Attenuation of lipopolysaccharide-induced inflammatory response and phospholipids metabolism at the feto-maternal interface by N-acetyl cysteine. Pediatr. Res. 2008, 64:334-339.
159. Papiol S., Molina V., Desco M., Rosa A., Reig S., Sanz J., Palomo T., Fananas L. Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin-1 beta gene (2q13). Genes Brain Behav. 2008, 7:796-801.
160. Park S.W., Lee S.K., Kim J.M., Yoon J.S., Kim Y.H. Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neurosci. Lett. 2006, 402:25-29.
161. Parker G., Gibson N.A., Brotchie H., Heruc G., Rees A.M., Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am. J. Psychiatry 2006, 163:969-978.
162. Pasco J.A., Jacka F.N., Williams L.J., Henry M.J., Nicholson G.C., Kotowicz M.A., Berk M. Leptin in depressed women: cross-sectional and longitudinal data from an epidemiologic study. J. Affect. Disord. 2008, 107:221-225.
163. Pasco J.A., Jacka F.N., Williams L.J., Henry M.J., Nicholson G.C., Kotowicz M.A., Berk M. Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin, and the risk of de novo major depression. Psychother. Psychosomat. 2010.
164. Pasco J.A., Kotowicz M.A., Henry M.J., Nicholson G.C., Spilsbury H.J., Box J.D., Schneider H.G. High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA 2006, 296:1353-1355.
165. Pasco J.A., Nicholson G.C., Ng F., Henry M.J., Williams L.J., Kotowicz M.A., Hodge J.M., Dodd S., Kapczinski F., Gama C.S., Berk M. Oxidative stress may be a common mechanism linking major depression and osteoporosis. Acta Neuropsychiatr. 2008, 20:112-116.
166. Pene F., Courtine E., Cariou A., Mira J.P. Toward theragnostics. Crit. Care Med. 2009, 37:S50-S58.
167. Piletz J.E., Halaris A., Iqbal O., Hoppensteadt D., Fareed J., Zhu H., Sinacore J., Lindsay Devane C. Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J. Biol. Psychiatry 2008, 1-11.
168. Plein H., Berk M. Changes in the platelet intracellular calcium response to serotonin in patients with major depression treated with electroconvulsive therapy: state or trait marker status. Int. Clin. Psychopharmacol. 2000, 15:93-98.
169. Plein H., Berk M. The platelet as a peripheral marker in psychiatric illness. Hum. Psychopharmacol. 2001, 16:229-236.
170. Post R.M. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am. J. Psychiatry 1992, 149:999-1010.
171. Post R.M. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci. Biobehav. Rev. 2007, 31:858-873.
172. Qian H.R., Yang Y. Neuron differentiation and neuritogenesis stimulated by N-acetylcysteine (NAC). Acta Pharmacol. Sin. 2009, 30:907-912.
173. Rao J.S., Bazinet R.P., Rapoport S.I., Lee H.J. Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kappaB DNA binding activity and COX-2 mRNA. Bipolar Disord. 2007, 9:513-520.
174. Rao J.S., Harry G.J., Rapoport S.I., Kim H.W. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol. Psychiatry 2010, 15:384-392.
175. Rees J.N., Florang V.R., Anderson D.G., Doorn J.A. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate. Chem. Res. Toxicol. 2007, 20:1536-1542.
176. Reynolds J.L., Ignatowski T.A., Sud R., Spengler R.N. Brain-derived tumor necrosis factor-alpha and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant. J. Pharmacol. Exp. Ther. 2004, 310:1216-1225.
177. Robinson L.J., Ferrier N. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord. 2006, 8:103-116.
178. Rosa A.R., Frey B.N., Andreazza A.C., Cereser K.M., Cunha A.B., Quevedo J., Santin A., Gottfried C., Goncalves C.A., Vieta E., Kapczinski F. Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neurosci. Lett. 2006, 407:146-150.
179. Ross B.M., Seguin J., Sieswerda L.E. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?. Lipids Health Dis. 2007, 6:21.
180. Roy-Byrne P., Post R.M., Uhde T.W., Porcu T., Davis D. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatrica Scand. Supplementum 1985, 317:1-34.
181. Sassi R.B., Nicoletti M., Brambilla P., Mallinger A.G., Frank E., Kupfer D.J., Keshavan M.S., Soares J.C. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci. Lett. 2002, 329:243-245.
182. Schwarcz R., Whetsell W.O., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219:316-318.
183. Scott J., Paykel E., Morriss R., Bentall R., Kinderman P., Johnson T., Abbott R., Hayhurst H. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Brit. J. Psychiatry 2006, 188:313-320.
184. Shao L., Martin M.V., Watson S.J., Schatzberg A., Akil H., Myers R.M., Jones E.G., Bunney W.E., Vawter M.P. Mitochondrial involvement in psychiatric disorders. Ann. Med. 2008, 40:281-295.
185. Smith A.J., Stone T.W., Smith R.A. Neurotoxicity of tryptophan metabolites. Biochem. Soc. Trans. 2007, 35:1287-1289.
186. Solin M.S., Ball M.J., Robertson I., de Silva A., Pasco J.A., Kotowicz M.A., Nicholson G.C., Collier G.R. Relationship of serum leptin to total and truncal body fat. Clin. Sci. (Lond). 1997, 93:581-584.
187. Stafford, L., Berk, M. The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: Proof of concept for the inflammatory and oxidative hypotheses of depression? J. Clin. Psychiatry, in press.
188. Stokes A.H., Hastings T.G., Vrana K.E. Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res. 1999, 55:659-665.
189. Stone T.W., Perkins M.N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 1981, 72:411-412.
190. Strakowski S.M., DelBello M.P., Zimmerman M.E., Getz G.E., Mills N.P., Ret J., Shear P., Adler C.M. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. Am. J. Psychiatry 2002, 159:1841-1847.
191. Stuchebrukhov A.A. Mechanisms of proton transfer in proteins: localized charge transfer versus delocalized soliton transfer. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 2009, 79:031927.
192. Sun X., Wang J.F., Tseng M., Young L.T. Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J. Psychiatry Neurosci. 2006, 31:189-196.
193. Swann A.C., Bowden C.L., Calabrese J.R., Dilsaver S.C., Morris D.D. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in mania. Am. J. Psychiatry 1999, 156:1264-1266.
194. Szelenyi J., Vizi E.S. The catecholamine cytokine balance: interaction between the brain and the immune system. Ann. N. Y. Acad. Sci. 2007, 1113:311-324.
195. Tavares R.G., Tasca C.I., Santos C.E., Alves L.B., Porciuncula L.O., Emanuelli T., Souza D.O. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem. Int. 2002, 40:621-627.
196. Tramontina J.F., Andreazza A.C., Kauer-Sant'anna M., Stertz L., Goi J., Chiarani F., Kapczinski F. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci. Lett. 2009, 452:111-113.
197. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 2006, 9:519-525.
198. Turnbull T., Cullen-Drill M., Smaldone A. Efficacy of omega-3 fatty acid supplementation on improvement of bipolar symptoms: a systematic review. Arch. Psychiatr. Nurs. 2008, 22:305-311.
199. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
200. Vincze I., Perroud N., Buresi C., Baud P., Bellivier F., Etain B., Fournier C., Karege F., Matthey M.L., Preisig M., Leboyer M., Malafosse A. Association between brain-derived neurotrophic factor gene and a severe form of bipolar disorder, but no interaction with the serotonin transporter gene. Bipolar Disord. 2008, 10:580-587.
201. Waddington J.L., Lane A., Scully P.J., Larkin C., O'Callaghan E. Neurodevelopmental and neuroprogressive processes in schizophrenia. Antithetical or complementary, over a lifetime trajectory of disease?. Psychiatr. Clin. North Am. 1998, 21:123-149.
202. Wadee A.A., Kuschke R.H., Wood L.A., Berk M., Ichim L., Maes M. Serological observations in patients suffering from acute manic episodes. Hum. Psychopharmacol. 2002, 17:175-179.
203. Walz J.C., Andreazza A.C., Frey B.N., Cacilhas A.A., Cereser K.M., Cunha A.B., Weyne F., Stertz L., Santin A., Goncalves C.A., Kapczinski F. Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder. Neurosci. Lett. 2007, 415:87-89.
204. Walz J.C., Magalhaes P.V., Giglio L.M., Cunha A.B., Stertz L., Fries G.R., Andreazza A.C., Kapczinski F. Increased serum neurotrophin-4/5 levels in bipolar disorder. J. Psychiatr. Res. 2009, 43:721-723.
205. Wang D.W., Zhou R.B., Yao Y.M. Role of cholinergic anti-inflammatory pathway in regulating host response and its interventional strategy for inflammatory diseases. Chin. J. Traumatol. 2009, 12:355-364.
206. Wang J.F., Shao L., Sun X., Young L.T. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord. 2009, 11:523-529.
207. Welin D., Novikova L.N., Wiberg M., Kellerth J.O., Novikov L.N. Effects of N-acetyl-cysteine on the survival and regeneration of sural sensory neurons in adult rats. Brain Res. 2009, 1287:58-66.
208. Williams L.J., Pasco J.A., Jacka F.N., Henry M.J., Dodd S., Berk M. Depression and bone metabolism. A review. Psychother. Psychosom. 2009, 78:16-25.
209. Xu J., Liu Y., Wang P., Li S., Wang Y., Li J., Zhou D., Chen Z., Zhao T., Wang T., Xu H., Yang Y., Feng G., He L., Yu L. Positive association between the brain-derived neurotrophic factor (BDNF) gene and bipolar disorder in the Han Chinese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:275-279.
210. Yasuda S., Liang M.H., Marinova Z., Yahyavi A., Chuang D.M. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol. Psychiatry 2009, 14:51-59.
211. Yoon S.J., Lyoo I.K., Haws C., Kim T.S., Cohen B.M., Renshaw P.F. Decreased glutamate/glutamine levels may mediate cytidine's efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2009, 34:1810-1818.
212. Yuksel C., Ongur D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol. Psychiatry 2010.
213. Zis A.P., Grof P., Webster M., et al. Prediction of relapse in recurrent affective disorder. Psychopharmacol. Bull. 1980, 16:47-49.
214. Zou J., Wang Y.X., Dou F.F., Lu H.Z., Ma Z.W., Lu P.H., Xu X.M. Glutamine synthetase down-regulation reduces astrocyte protection against glutamate excitotoxicity to neurons. Neurochem. Int. 2010, 56:577-584.
215. Zuo D.Y., Wu Y.L., Yao W.X., Cao Y., Wu C.F., Tanaka M. Effect of MK-801 and ketamine on hydroxyl radical generation in the posterior cingulate and retrosplenial cortex of free-moving mice, as determined by in vivo microdialysis. Pharmacol. Biochem. Behav. 2007, 86:1-7.